

SMBD - JEWISH GENERAL HOSPITAL

McGILL UNIVERSITY

DEPARTMENT OF MEDICINE

ANNUAL REPORT

2006 -2007

**Submitted by
Dr. Ernesto L. Schiffrin
Physician-in-Chief**

DEPARTMENT OF MEDICINE - SMBD - JEWISH GENERAL HOSPITAL

2006-2007

TABLE OF CONTENTS

- 1. ACADEMIC HIGHLIGHTS / OBJECTIVE AND PRIORITIES**
- 2. GRAND MEDICAL ROUNDS & INVITED SPEAKERS**
- 3. UNDERGRADUATE AND POSTGRADUATE TEACHING REPORTS**
- 4. EXTERNAL RESEARCH GRANTS & AWARDS**
- 5. NEW HONORS, AWARDS AND APPOINTMENTS
(SEE APPENDIX A)**
- 6. PUBLICATIONS**
- 7. APPENDIX A. DIVISIONAL REPORTS**
 - 1. Division of Allergy and Clinical Immunology**
 - 2. Division of Cardiology**
 - 3. Division of Dermatology**
 - 4. Division of Endocrinology**
 - 5. Division of Gastroenterology**
 - 6. Division of Genetics**
 - 7. Division of Geriatric Medicine**
 - 8. Division of Hematology-Oncology**
 - 9. Division of Infectious Diseases**
 - 10. Division of Internal Medicine**
 - 11. Division of Medical Biochemistry**
 - 12. Division of Nephrology**
 - 13. Pulmonary Division**
 - 14. Division of Rheumatology**

1. ACADEMIC HIGHLIGHTS

I. Introduction

The Department has experienced another year of growth, stability and high-level productivity. With increasing clinical demands, the Department membership has risen to the challenge, maintaining significant research productivity and providing outstanding teaching to our residents and medical students. Although recruitment is limited by government restrictions of effectifs médicaux, we managed to add 4 full-time, one part-time and one associate members during the year March 2006 to April 2007. There has been one departure, Dr. W. Hammouda. The post of the Chief of Endocrinology has remained vacant due to lack of resources and space for this division. However, the recent promise by the administration to provide a doubling of the space allocated and renovate the present facilities will ensure the success of our current search, and it can be assumed that a new chief of the division will be in place shortly.

The progress and challenges of the Department during this last academic year are summarized below.

Faculty

A. Recruits

The following physicians have been recruited into the Department:

Dermatology – Dr. Genevieve Riberdy-Fortier (June 2006)
Cardiology – Dr. Dominique Joyal (July 2006)
Pulmonary – Dr. Carmela Pepe (July 2006)
Endocrinology – Dr. Stavroula Christopoulos (September 2006)
Rheumatology – Dr. M. Hudson (October 2006)

B. Changes of Status

The following physicians have left the Department:

Hematology – Dr. Wahbi Hammouda (February 2007)

C. Promotions

Dr. Nir Hilzenrat was promoted to Associate Professor (GFT-H).

II. Clinical Activities

Our CTU's continue to be well regarded by housestaff but they also note that the workload is very heavy. The ever-increasing demand from our Emergency Room has led the Department to be proactive and is now compiling data in this regard and devising plans to tackle the issue. One of the objectives from the teaching point of view has been to look into a reorganization of the

CTU's to ensure that the appropriate patient mix is offered to trainees. To assure clinical efficacy patients admitted to the CTU's from the Emergency are seen by the CTU teams as early as possible to reduce transfers between temporary wards. Despite the heavy clinical workload the Department continues to maintain high standards for teaching and clinical care.

The Cardiovascular Prevention Centre opened its doors in August 2006. With participation of several members of the Department, from the divisions of Internal medicine, Cardiology, Endocrinology and Nephrology, it has brought together medical experts from various fields for the treatment of patients with hypertension, dyslipidemia, obesity, metabolic syndrome, diabetes and other cardiovascular risk factors.

The Centre, located in Pavilion H, takes an integrated approach to the diagnosis and treatment of patients at high risk for developing cardiovascular disease. Medical therapies are complemented with lifestyle modifications such as weight control, smoking cessation and exercise. Due to the wide range of experts at the Centre, patients will be able to consult medical specialists from various disciplines, nutritionists, nurses, and in the future, psychologists, and a kinesiologist in the same centre.

The activities of the individual Divisions are summarized in the Divisional reports which are attached.

III. Teaching Activities

The Department continues its role in the teaching of both undergraduate medical students and resident physicians in general medicine and the subspecialties. Our members' dedication to teaching is well known and much appreciated by both medical students and residents. Dr. Berkson has held a 5-year education grant from the Arthritis Society since 2002.

Within the Department, the following staff and residents received awards:

Dr. Ernesto L. Schiffrin was inducted into the Royal Society of Canada in November 2006.

Dr. Khanna was awarded Teacher of the Year 2006 for the Division of Dermatology for McGill University.

Dr. Iliana Lega received the Dave Feder award. This award is presented to the resident who most practices medicine with compassion and sensitivity, displays kindness, respect and camaraderie towards colleagues and educators and carries a positive outlook enabling him/her to enjoy a meaningful balanced life beyond his/her profession.

Dr. Jonathan How was the recipient of the Sheldon Zelman Memorial Award given to for academic excellence and outstanding contribution to patient care.

Dr. Majid Al-Madi received the Dr. Allen Spanier Internal Medicine Award. This award is given to the resident who exhibits an enduring passion for the practice of medicine, through the

enjoyment of solving challenges of patient care and sharing solutions with others, while maintaining a high level of professionalism.

Dr. Ruxandra Bunea was voted as Teacher of the Year by the residents:

The past years of fewer residents has been reversed and will continue resulting in an improvement of the working conditions of residents and staff.

In 2006 – 2007 we recruited into our teaching program 9 R3, 10 R2, and 14 R1 housestaff. There were two Chief Residents, Dr. Beth-Ann Cummings and Marty Teltscher (July 2006-June 2007).

Grand Rounds: Of the 34 Grand Rounds given by the Department 16 featured speakers from outside the JGH, of whom 6 were from outside Quebec (see attached list).

Divisional Rounds: In addition to the above each Division manages its own teaching and research rounds as summarized in the attached reports.

IV. Research

The Department has instituted the Clinical Research Award Program in order to support and compensate full-time members of the Department involved in clinical research activities. The 2007 recipients of the Medicine Clinical Research awards are Drs. A. Dascal, C. Greenaway, A. Szilagyi and V. Tagalakis.

A detailed survey of research activities of the departmental members including grants and contracts (2006-2007) received has been compiled and is attached.

\$ 1,845,970	Clinical Investigator (including PhD) salary awards
\$16,161,674	Competitive Operating Grants (excluding associate members)
\$ 3,147,388	Contracts from Industry
\$ 40,000	Department of Medicine Clinical Research Awards
\$21,195,032	TOTAL
\$ 446,006	Postgraduate Fellows
\$ 3,677,284	Endowments & other
\$25,318,322	GRAND TOTAL

In the calendar year 2006, departmental members produced 257 peer reviewed original publications (excluding abstracts, reports, and other articles).

V. Departmental Activities

The Department continues to reinforce democratic and transparent management in all areas.

VI. MUHC and McGill

Our relationship with the MUHC has been characterized by collaboration and collegiality. Our commitment to excellence in teaching at both the undergraduate and postgraduate level continues to be valued by McGill University. There has been an increase in the number of medical students.

Dean Levin has reiterated that the JGH is a critical component of the McGill Faculty of Medicine and that he will ensure the support of our academic objectives. His support with respect to recruitment has been demonstrated in his allocating a Canada Research Chair to Dr. S. Lehoux, a cardiovascular scientist that we have recruited from Paris, France to the LDI, as well as support for the recruitment of a cardiovascular physician-scientist to enhance the basic and clinical research mission of the division of Cardiology while improving its ability to cope with its very large clinical and teaching load.

Within the hospital there continue to be serious strains regarding the Department's resources. It is hoped that we can proceed into the future with improved staff and space resource allocation to maintain our academic mission.

The Department gratefully recognizes the support of the Hospital Administration in its recruitment efforts.

2. OBJECTIVES AND PRIORITIES

It has been my priority from the first day of my tenure to ensure that the department continues to provide the excellent care to the patients of the hospital for which it is renowned, while at the same time maintaining its goals of excellence in teaching. I have tried to enhance the academic standing of the department within the McGill community by recruiting highly qualified and competitive physician scientists to reinforce the research capacity of the department and have a transformative effect that will enhance the ability of the hospital to serve as a translational science center. This requires not only finding the right individuals, but also being able to offer them adequate conditions that will be competitive with what they may receive from other top healthcare centers in North America and Europe. The latter task is challenging, due to constraints in funding for personal support, operating monies and up-to-date equipment, as well as difficulties in ensuring adequate space allocation and support services. Despite these difficulties and constraints, we are in the process of developing a "pipeline" of highly qualified clinician scientists in the areas of cardiology, endocrinology, hematology, pulmonary medicine, rheumatology and nephrology, some already in place, who are succeeding or have a good chance of success in scientific competition for the scarce resources currently available locally, provincially and nationally. We have put in place a program that will also help support the

research by GFTH physicians. We are planning fund raising events that will help provide to some degree the means to the department to accomplish these goals of enriching our staff to make sure that excellence in care, teaching and research are not only maintained but will continue to grow so that we may excel in our professional and academic activities. We believe that we can, despite current bureaucratic and funding constraints, achieve our objective of providing top care, teaching and a highly competitive clinical and translational research environment within the JGH Department of Medicine.

Respectfully submitted,

Ernesto L. Schiffrin, MD, PhD, FRSC, FRCPC
Physician-in-Chief

2. GRAND MEDICAL ROUNDS & INVITED SPEAKERS

Sept. 11	Clinical Update: Pain Management	James A. D. Otis, MD, Boston University School of Medicine
Sept. 18	Sunlight, Skin Cancer, Vitamin D and your Health	Manish Khanna, MD
Sept. 25	<u>19th Annual Bertha Mizne Memorial Lecture</u> : Upper GI Bleeding	Alan Barkun, MD, MUHC
Oct. 16	Clinical Challenges in the Treatment Of Lung Cancer: Are the Elderly Left Out?	Carmela Pepe, MD
Oct. 23	<u>McGill/Merck-Schering Lipid Lectureship</u> : HDL: The New Frontier in the Treatment of Cardiovascular Disease	Bryan Brewer, MD, Washington Hospital Center, Washington, DC
Oct. 30	Patients and Cholesterol: Lessons Learned and Lessons Applied	Jacques Genest, MD, MUHC
Nov. 6	Approach To Multiple Antibiotic Hypersensitivity	Fanny Silviu-Dan, M, MUHC
Nov. 13	<u>McGill-Jgh-Glaxosmithkline Lectureship In Metabolism</u> : Beta Cell: Friend and Foe	Steven E. Kahn, MB, ChB, University of Washington School of Medicine
Nov. 20	<u>Refresher about Spinal Cord Compression as an Oncological Emergency</u>	Khalil Sultamen, MD,
Nov. 27	Outcome of Patients with High Risk Hematological Malignancies Treated with Adoptive Immunotherapy	Martin Gyger, MD
Dec. 4	Mobility: Emerging Clinical Value to Generalists and Specialists	Stephanie Studenski, MD, MPH, University of Pittsburgh
Dec. 11	Guts, Gaits and Wasting Quokkas - A Case Study in Redox Neurology	Alexandre Henri-Bhargava, MD, MUHC & Hyman Schipper, MD
Dec. 18	Management of Hospital and Ventilator-Associated Pneumonia: How Are We Doing?	Denny Laporta, MD
Jan. 15	The Aging Heart	Jonathan Afilalo, MD, Int. Med. Resident
Jan. 22	Saving Lives in Northern Quebec - What they Forgot to Teach me in Medical School	Bert Govig, MD. C.H. Hôtel-Dieu d'Amos
Jan. 29	A Winter's Tale: Community-Acquired Pneumonia and Influenza	Timothy Brewer, MD, MUHC
Feb. 5	Pharmacogenetics in Heart Failure: Science Fiction or Reality	Richard Sheppard, MD
Feb. 12	Eleventh Annual Humanization of Care Awareness Program: Families in Crisis: What Can Health Professionals Do to Support Coping with Illness?	Fabie Duhamel, RN, PhD, CHUM
Feb. 19	Dendritic Cells: From Discovery to Clinical Applications	Devi Banerjee, MD, MUHC
Feb. 26	A Stitch in Time...? - Management Dilemmas in Hereditary Gastric Cancer	Marc Tischkowitz, MD, Jacob Garzon, MD & Adrian Gologan, MD
Mar. 5	Cardiac Tumors	Regina Husa, MD & Felix Ma, MD
Mar. 12	New Canadian Guidelines for Diagnosis and Treatment of Dementia: Results of a Consensus Conference	Howard Chertkow, MD
Mar. 19	The Top 5 Studies in Hypertension Over the Last 15 Years and Implications	Pierre Larochelle, MD, CHUM
Mar. 26	The Cushingoid Brain: Effects of Glucocorticoids on Neuroanatomy and Function	Stavroula Christopoulos, MD
Apr. 2	Prophylactic HPV Vaccines: Potential for a Sea Change	Alex Ferenczy, MD
Apr. 16	Targeting Abdominal Obesity for Optimal Management of Global Cardiovascular Disease Risk	Jean-Pierre Després, PhD, FAHA Université Laval
Apr. 23	What's New in Acute Stroke	Jeffrey Minuk, MD
Apr. 30	New Strategies in the Treatment of COPD	Andrew Hirsch, MD & Mark Palayew, MD
May 7	The Nat Kaufman Memorial Lecture in Hematology: Recent Advances in the Treatment of CLL (Chronic Lymphocytic Leukemia)	Kanti R. Rai, MD, Albert Einstein College of Medicine, New York
May 14	Scleroderma - An Update and the Canadian Perspective	Murray Baron, MD & Marie Hudson, MD
May 28	<u>Ethics Rnds</u> : Levels of Intervention for Resuscitation and Other Critical Interventions	Paul Warshawsky, MD
Jun. 4	Nitric Oxide and Cardiac Remodeling: Insights from Murine Echocardiography	Marielle Scherrer-Crosbie, MD, Harvard Medical School, Boston, MA
Jun. 11	Clostridium Difficile-Associated Disease (CDAD): What We Know, What We Don't Know, and What We Learned from the Quebec Epidemic	Mark A. Miller, MD
Jun. 18	Late Thrombosis and Drug-Eluting Stents	Mark J. Eisenberg, MD

3. UNDERGRADUATE AND RESIDENT TEACHING REPORTS

A. REPORT OF UNDERGRADUATE TEACHING - JUNE 2007

The Professional Skills course (physical diagnosis) and Introduction to Internal Medicine (ICM-B) have gone well. For the first time in hour history one student failed Professional Skills. There were

35 Professional Skills

61 Introduction to Internal Medicine students

48 Practice of Medicine (clerks).

Over the years it has become increasingly difficult to recruit teachers in all areas. For this reason, at the recommendation of Dr. L. Berkson, and later Dr. E. MacNamara, a new system has been devised.

POM: There is a new form entitled “minimum clinical exposures” that all site coordinators are to include and given to each clerk at orientation.

Respectfully submitted,

Michael Gold, MD
Director of Undergraduate Education

B. REPORT OF POSTGRADUATE TEACHING - JUNE 2007

There will be 12 incoming R1's to the program starting July 2007. A positive change this year is that 5 of these 12 chose the JGH as their first choice site for training, up from just 1 last year. This is a credit to the both the current residents and all staff involved with the residents who continue to ensure high quality teaching and a relaxed environment conducive to learning despite the heavier workload as compared to the other teaching sites.

Academic ½ days: These are now a permanent fixture in the McGill training program and occur almost every Thursday for different cohorts. The ethics and communication skills ½ days were held at the McGill Simulation Centre and were well received by both the residents and staff who participated. Thanks to all those staff who were involved this year. This ½ day will be part of the yearly curriculum. This year, the program is also looking at using the Simulation Centre for procedures training.

Electives booking: Based on prior feedback from subspecialties, we are now booking the residents' electives at the start of the year. They are aware that they may not change these bookings once they are made without discussing it with the program director first. Hopefully this will eliminate the problem of unpredictability in numbers of trainees in each period for each subspecialty service.

Lounge: The residents' lounge on 8Nw is in full use and the residents love it. It is a comfortable, quiet space that is much used by the residents and has definitely contributed to the overall improvement in residents' morale over the last year. There are concerns with the new renovation plans for that floor that the lounge may be affected, and these concerns have been addressed to Drs. Schiffrin and Portnoy, both of whom had been instrumental in the creation of the lounge.

Resident Research Award: We will formally create a resident research award as they do at the other sites in order to promote and recognize excellence in research at the residents' level. This will be given at the end of the year along with the other yearly awards.

Main Issue for Upcoming Year: As many know, Family Medicine (FM), for a variety of reasons, did not fill many of their positions for the 07-08 academic year. This has led that program to reevaluate the structure of their training program. This has many implications for the Internal Medicine Training Program (IM) and the Department of Medicine in general.

With fewer FM residents, the CTU's (7W, 7NW, CCU) will be harder to staff as there are not enough IM residents to fill in, especially if FM pulls out of 7W completely starting in the 08-09 year. We cannot increase the number of periods the IM residents do on the CTU's as this must be equal to the number done at the MUHC. Therefore daytime coverage of the current number of patients on the CTU's with the projected numbers of IM residents is impossible without adversely affecting patient care and the learning experience of our trainees. Note that IM resident numbers are not expected to increase beyond the 12/year we get now. Nighttime coverage will also be affected as FM will be pulling out of their current responsibilities not only on our CTUs but also on Geriatrics and IM cannot pick up this excess coverage without adversely affecting patient care and the learning experience of our trainees.

In order to address these very serious shortages, changes will have to be implemented at the Department and Hospital levels which will likely have an impact on everyone. These are still being discussed. It is imperative while we look at these changes to ensure that we maintain the excellence that is perceived by our trainees in order to maintain morale and continue having more excellent students choose the JGH as their first choice site for IM training.

Respectfully submitted,

Michelle Elizov, MD
Director of Postgraduate Education

GENERAL INTERNAL MEDICINE HOUSESTAFF LIST 2006-2007

CHIEF RESIDENT

Cummings, Beth (July-December 2006)

Teltscher, Marty (January-June 2006)

R3

Al-Wazaq, Sara

Al-Madi, Majid

Al-Hejily, Wesam

Afilalo, Jonathan

Lega, Iliana

Malakzadeh, Pardis

Speranza, Giovanna

Teltscher, Marty

Tsien, Cynthia

R2

Al-Qambar, Mohammed

Bouganim, Nathaniel

Hofmann, Adam

How, Jonathan

Jacques, Cindi

Lalonde, Andrea

Lin, Charles

Lipes, Jed

Nguyen, Jennifer

Ramadhan, Abdulaziz

R1

Abualsaud, Ali

Al-Touri, Sultan

Al-Zeedy, Khalfan

Beauchamp, Elizabeth (Lisa)

Davison, Kelly

Dayan, Natalie

7-11)

Luk, Cynthia

Saad, Nathalie

Schwartz, Blair

Tisseverasinghe, Annaliese

Toldeano, Thierry

Yu, Oriana Hoi Yun

Zhai, Alexander

OTHER PROGRAMS

Abikzher, Gad (Nuclear Medicine)

Al-Fardan, Fahad (Ophthalmology)

Al-Kharashi, Majed (Ophthalmology)

Gallant, Aimee (Radiation Oncology)

Li, Jian (Diagnostic Radiology periods 1-6)

Mvilongo, Eding (Anesthesia periods 1-3 &

Yu, Daniel (Ophthalmology)

4. EXTERNAL RESEARCH GRANTS & AWARDS

A. Career Award – July 2006 – June 2007 (Clinician-Scientists)

Name	Agency	Expiry Date	Amount
BERKSON, Dr. L.	Arthritis Society	June 30, 2007	45 000
BLOSTEIN, Dr. M.	FRSQ	June 30, 2009	36 848
DUQUE, Dr. G.	FRSQ	June 30, 2008	36 159
EISENBERG, Dr. M.	FRSQ	June 30, 2008	36 159
GALIPEAU, Dr. J.	CIHR	June 30, 2008	62 563
GREENAWAY, Dr. C.	FRSQ	June 30, 2009	38 840
HUDSON, Dr. M.*	Arthritis Society	Jan-Jun, 2007	15 000
KAHN, Dr. S.	FRSQ	June 30, 2009	39 377
KARAPLIS, Dr. A.	CIHR	June 30, 2007	89 178
PEPE, Dr. C.	CIHR	March 31, 2009	10 000
SCHIFFRIN, Dr. E.	Canada Research Chair (CFI-CIHR)	December 31, 2012	120 000
TAGALAKIS, Dr. V.	FRSQ	June 30, 2008	<u>30 250</u>
TOTAL:			559 374

B. Grants & Bursaries 2006-2007

See attached Excel File

5. NEW HONORS, AWARDS AND APPOINTMENTS (SEE APPENDIX A)

6. PUBLICATIONS (January – December 2006)

Alaoui-Jamali, Moulay

--Balys R, **Alaoui-Jamali M**, Hier M, Black M, Domanowski G, Rochon L, Jie S. Clinically relevant oral cancer model for serum proteomic eavesdropping on the tumour microenvironment. *Journal of Otolaryngology*. 35:157-66, 2006

--Kalra J, Shao Q, Qin H, Thomas T, **Alaoui-Jamali MA**, Laird DW. Cx26 inhibits breast MDA-MB-435 cell tumorigenic properties by a gap junctional intercellular communication-independent mechanism. *Carcinogenesis*. 27:2528-37, 2006

--Hernandez M, Shao Q, Yang XJ, Luh SP, Kandouz M, Batist G, Laird DW, **Alaoui-Jamali MA**. A histone deacetylation-dependent mechanism for transcriptional repression of the gap junction gene cx43 in prostate cancer cells. *The Prostate*. 66:1151-1161, 2006

--**Alaoui-Jamali MA**. Protein tyrosine kinase signaling diversity and susceptibility to targeted kinase inhibitors. *Biomedicine Pharmacotherapy*. 60:629-32, 2006 (invited review).

--**Alaoui-Jamali MA** and Xu Y. Proteomic technology for biomarker profiling in cancer: an update. *Journal of Zhejiang University Science*. 7:411-20, 2006 (invited review)

--Luh S-P and **Alaoui-Jamali MA**. New targets, new agents, and the evolving phenomena of drug resistance. *Current Cancer Therapy Reviews*, 2:23-30, 2006

Autexier, Chantal

--Cerone MA, Londono-Vallejo JA, **Autexier C**. Telomerase inhibition enhances the response to anti-cancer drug treatment in human breast cancer cells. *Molecular Cancer Therapeutics*, 5:1669-1675, 2006

--Cerone MA, Londono-Vallejo JA, **Autexier C**. Mutated telomeres sensitize tumor cells to anti-cancer drugs independently of telomere shortening and mechanisms of telomere maintenance. *Oncogene*, 25:7411-7420, 2006

--**Autexier C**, Lue NF. The structure and function of Telomerase Reverse Transcriptase (TERT). *Annual Review of Biochemistry*, 75:493-517, 2006

--Marie-Egyptienne DT, **Autexier C**. Anomalies du complexe de la télomérase en pathologie hématologique. *Hématologie*, 12:267-273, 2006

Baron, Murray

--Dobkin P, De Civita M, Abrahamowicz M, **Baron M**, Bernatsky S. Predictors of Health Status in Women with Fibromyalgia : A Prospective Study. *International J of Behavioral Medicine*, 13:101-8, 2006

--Pukall C, **Baron M**, Amsel R, Khalifé F, Binik Y. Tender point examination in women with vulvar vestibulitis syndrome. *Clinical Journal of Pain*, 22:601-9, 2006

Beitel, Lenore

--Elhaji, YA, Stoica, I, Dennis, S, Purisima, EO, Lumbroso, R, **Beitel, LK, Trifiro, MA**. Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity. *Hum Mol Genet*, 15: 921-931, 2006 [Corrigendum: *Hum Mol Genet* 15: 561, 2006]

Béland, Francois

--Savard, J, Lebel, P, Leduc, N, **Béland, F**, Bergman, H. Caregiver satisfaction with support services: Influence of different types of services. *Journal of Aging and Health*. 18:3-27, 2006

--**Béland F**, Bergman H, Lebel P, et al. A System of Integrated Care for Frail Older Persons (SIPA) in Canada: Results from a Randomized Controlled Trial. *J of Gerontol A Biol Sc, Med Sci.*, 61A: 4: 367–373, 2006

--**Béland F**, Bergman H, Lebel P, Denis JL, Contadriopoulos AP, Tousignant P, Dallaire L, Fletcher J. Integrated Services for Frail Elders (SIPA): A trial of a Model for Canada. *Can Jour on Aging*. 25): 25-42, 2006. Also published in French: Des services intégrés pour les personnes âgées fragiles (SIPA): expérimentation d'un modèle pour le Canada. *Revue canadienne sur le vieillissement*, 25:5-24, 2006

Bergman, Howard

--Touchon, **Bergman H**, Bullock R, Rapatz G, Nagel J, Lane R. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology. *Current Medical Research and Opinion*. 22:49-59, 2006

--Bullock R, **Bergman H**, Touchon J, Gambina G, He Y, Nagel J, Lane R. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. *Current Medical Research and Opinion*, 22:483-494, 2006

--**Bergman H**, Hogan D, Karunanathan S, Béland F, Wolfson C. Frailty. *The Encyclopedia of Aging*, 4th edition, 1:423-426, 2006

Chertkow Howard

--Levinoff EJ, Phillips NA, Verret L, Babins L, Kelner N, Akerib V, & **Chertkow H**. Cognitive estimation impairment in Alzheimer disease and Mild Cognitive Impairment. *Neuropsychology*, 20:123–132, 2006

--Feldman H, Gauthier S, **Chertkow H**, Conn D K, Freedman M, & MacKnight CR for the 2nd Canadian Conference on Antidementia Guidelines. Canadian Guidelines for the Development of Antidementia Therapies: a Conceptual Summary. *Canadian Journal of Neurological Sciences*, 33:6-26, 2006

--Gauthier S, Reisberg B, Zaudig M, Peterson R, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, **Chertkow H**, Cummings J L, De Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney M, Whitehouse P, & Winblad B, on behalf of the participants of the International Psychogeriatric Association Expert Conference on MCI. Mild Cognitive Impairment. *Lancet*, 367:1262-1270, 2006

--Doniger GM, Dwolatzky T, Zucker DM, **Chertkow H**, Crystal H, Schweiger A, & Simon ES. Computerized cognitive testing battery identifies MCI and mild dementia even in the presence of depressive symptoms". *American Journal of Alzheimer's Disease and Other Dementias*, 2:28-36, 2006

--Duong A, Whitehead V, Hanratty K, & **Chertkow H**. The nature of lexico-semantic processing deficits in Mild Cognitive Impairment. *Neuropsychologia*, 44:1928-1935, 2006

--**Chertkow H**. Treating Mild Cognitive Impairment. *The Canadian Review of Alzheimer's Disease and Other Dementias*. 4-15, 2006

--Maes OC, Kravitz S, Mawal Su H, Liberman A, Mehindate K, Berlin D, Sahlas DJ, **Chertkow HM**, Bergman H, Melmed C, & Schipper HM. Characterization of α 1-antitrypsin as a heme oxygenase-1 suppressor in Alzheimer plasma. *Neurobiology of Disease*. 24:89–100, 2006

--**Chertkow H**. Emerging pharmacological therapies for Mild Cognitive Impairment. In H Tuokko and DF Hultsch (Eds), International Perspectives on Mild Cognitive Impairment. pp 217-243, 2006

--**Chertkow H**. Chapter 18, Management in the very early stage of dementia. In Serge Gauthier (Ed), Clinical Diagnosis and Management of Alzheimer's Disease, Third Edition, pp 205-221, 2006

Clarfield, Avrum

--Clarfield AM, Monette J, Bergman H, Monette M, et al. Enteral Feeding in End-Stage Dementia: A Comparison of Religious, Ethnic, and National Differences in Canada and Israel. *J of Gerontol: Med Sci*. Vol 61A:621-627, 2006

Cohen, Albert

--De Jager PL, Sawcer S, Waliszewska A, Farwell L, Wild G, **Cohen A**, Langelier D, Bitton A, Compston A, Hafler DA, Rioux JD: Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis. *Eur J Hum Genet.* 14:317-21, 2006

Cohen, S Robin

--Lee V, **Cohen SR**, Edgar L, Laizner AM, Gagnon A. Meaning-making and Psychological Adjustment to cancer: development of an intervention and pilot results. *Oncology Nursing Forum*, 33:291-302, 2006

--Lee V, **Cohen SR**, Edgar L, Laizner AM, Gagnon AJ. Meaning-making intervention during breast or colorectal cancer treatment improves self-esteem, optimism, and self-efficacy. *Social Science & Medicine*, 62: 3133-3145, 2006

--Macdonald ME, Liben S, **Cohen SR**. Truth and consequences: Parental perspectives on autopsy after the death of a child. *Pediatric Intensive Care Nursing*, 7: 6-15, 2006

--Williams A, Crooks VA, Stajduhar KI, Allan D, **Cohen SR**. Improving Canada's Compassionate Care Benefit: Views of family caregivers in chronic illness. *International Journal of Palliative Nursing*, 12: 438-45, 2006

--**Cohen SR**, Leis AM, Kuhl D, Charbonneau C, Ritvo P, Ashbury FD. QOLLI-F: measuring family carer quality of life. *Palliative Medicine*, 20:755-767, 2006

--**Cohen SR**. Quality of life assessment in palliative care. In: *Textbook in Palliative Medicine*, E. Bruera, I. Higginson, C. von Gunten, and C. Ripamonti eds. Hodder Arnold Limited, London, England. Distributed by Oxford University Press, New York, N.Y. pp. 349-55, 2006

Cohen, Victor

--**Cohen V**, Agulnik JS, Jarry J, Batist G, Small D, Kreisman H, Tejada A, Miller WH Jr, Chong G. Evaluation of Denaturing High-Performance Liquid Chromatography as a Rapid Detection Method for Identification of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. *Cancer*, 107:2858-2865, 2006

Douala-Bell, Florence

--**Douala-Bell F**, Avalos A, Brenner B, Gaolathe T, Mine M, Gaseitsiwe S, Oliveira M, Moist D, Ndwapi N, Moffat H, Essex M, Wainberg MA. High Prevalence of the K65R Mutation in Human Immunodeficiency Virus-Infected Batswana Patients Treated with ddi-based regimens. *Antimicrob Agents Chemother*, 50:4182-4185, 2006

--**Douala-Bell F**, Avalos A, Gaolathe T, Mine M, Gaseitsiwe S, Ndwapi N, Novitsky VA, Brenner B, Oliveira M, Moist D, Moffat H, Thior I, Essex M, Weinberg MA. Impact of HIV-1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen. *Antimicrob Agents Chemother*, 50:2210-2213, 2006

--Brenner B, Oliveira M, **Douala-Bell B**, Moist DD, Ntemgwa M, Frankel F, Essex M and Weinberg MA. HIV-1 Subtype C Viruses Rapidly Develop K65R Resistance to Tenofovir in Cell Culture. *AIDS* 20:F9-F13, 2006

Duque, Gustavo

--Retornaz F, **Duque G**. Osteoporosis in the elderly. *Presse Med*. 35(10 Pt 2):1547-56, 2006

--**Duque G**, Mallet L, Roberts A, Gingrass S, Kremer R, Sainte-Marie LG, Kiel DP. To treat or not to treat, that is the question. Proceedings of the Quebec Symposium for the Treatment of Osteoporosis in Long-term Care Institutions, Saint-Hyacinthe, Quebec, November 5, 2004. *J Am Med Dir Assoc*. Sep, 7:435-41, 2006

--**Duque G**. Dietetic assistants improved postoperative clinical outcomes in older women with hip fracture. *ACP J Club*. Sep-Oct, 145:40, 2006

--**Duque G**, Rivas D. Age-related changes in lamin A/C expression in the osteoarticular system: laminopathies as a potential new aging mechanism. *Mech Ageing Dev*. 127:378-83, 2006

--Vecino-Vecino C, Gratton M, Kremer R, Rodriguez-Manas L, **Duque G**. Seasonal variance in serum levels of vitamin d determines a compensatory response by parathyroid hormone: study in an ambulatory elderly population in Quebec. *Gerontology*. 52:33-9, 2006

--**Duque G**, Finkelstein A, Roberts A, Tabatabai D, Gold SL, Winer LR; Members of the Division of Geriatric Medicine, McGill University. Learning while evaluating: the use of an electronic evaluation portfolio in a geriatric medicine clerkship. *BMC Med Educ*. 12:6:4, 2006

-- **Duque G**, Martin, Troen B. Aging and Nutrition (Third Edition). Chapter 12: Skeletal Aging. Ed. Ronni Chernoff, pp 325-343, 2006

--**Duque G**. Le précis pratique de Geriatrie. Chapter 46: Ostéoporose. Ed. Marcel Arcand and Rejean Hebert, 2006

Eintracht, Shaun

--Mattman A, **Eintracht S**, Mock T, Schick G, Seccombe DW, Hurley RM, White CT, Estimating pediatric glomerular filtration rates in the era of chronic kidney disease staging, *J Am Soc Nephrol*, 17: 487-96, 2006

Eisenberg, Mark

--Birnbaum LM, Filion KB, Joyal D, **Eisenberg MJ**. Second reading of coronary angiograms by radiologists. *Can J Cardiol*, 22:1217-2221, 2006

--Huynh T, O'Loughlin J, Joseph L, Schampaert E, Rinfret S, Afilalo M, Kouz S, Cantin B, Nguyen M, **Eisenberg MJ**. AMI-QUEBEC Study Investigators. Delays to reperfusion therapy in acute ST-segment elevation myocardial infarction: results from the AMI-QUEBEC Study. *CMAJ*, 175:1527-32, 2006

--Halabi AR, Beck CA, **Eisenberg MJ**, Richard H, Pilote L. Impact of on-site cardiac catheterization on resource utilization and fatal and non-fatal outcomes after acute myocardial infarction. *BMC Health Serv Res*, 6:148, 2006

--Violette PD, Filion KB, Haider S, Pilote L, **Eisenberg MJ**. A cost analysis of nonelective coronary artery bypass graft surgery. *J Card Surg*, 21:621-7, 2006

--**Eisenberg MJ**. Drug eluting stents: the price is not right. *Circulation*, 114:1745-54, 2006

--Okraïec K, Pilote L, Platt R, **Eisenberg MJ**. Use of cardiovascular medical therapy among patients undergoing coronary artery bypass graft surgery: results from the ROSETTA-CABG registry. *Can J Cardiol*, 22:841-7, 2006

--**Eisenberg MJ**, Konnyu KJ. Drug-eluting stents for the prevention of in-stent restenosis. *Am J Cardiol*, 98:375-82, 2006

--Kurzenewyg D, Filion KB, Pilote L, Nault P, Platt RW, Rahme E, Steinmetz O, **Eisenberg MJ**. Cardiac Medical Therapy among Patients Undergoing Abdominal Aortic Aneurysm Repair. *Ann Vasc Surg*, 20:569-76, 2006

--Wou K, Nguyen H, Duerr R, Del Core M, Fourchy D, Huynh T, Lader E, Rogers FJ, Chaudhry R, Pilote L, **Eisenberg MJ**. Impact of functional testing results on prescription patterns of anti-anginal medication after coronary artery bypass graft surgery: results from the ROSETTA-CABG Registry. *J Invasive Cardiol*, 18:278-82, 2006

--**Eisenberg MJ**, Wou K, Nguyen H, Duerr R, Del Core M, Fourchy D, Huynh T, Lader E, Rogers FJ, Chaudhry R, Okraïec K, Pilote L. Lack of benefit for routine functional testing early after coronary artery bypass graft surgery: results from the ROSETTA-CABG Registry. *J Invasive Cardiol*, 18:147-52, 2006

--**Eisenberg MJ**, Wou K, Nguyen H, Duerr R, Del Core M, Fourchy D, Huynh T, Lader E, Rogers FJ, Chaudhry R, Okraïec K, Pilote L. Use of stress testing early after coronary artery bypass graft surgery. *Am J Cardiol*, 97:810-6, 2006

--**Eisenberg MJ**. An American physician in the Canadian health care system. *Arch Intern Med*, 166:281-2, 2006

--**Eisenberg MJ**, Gioia LC. Angiotensin II receptor blockers in congestive heart failure. *Cardiol Rev*, 14:26-34, 2006

Foulkes, William

Soravia C, Delozier CD, Dobbie Z, Berthod CR, Arrigoni E, Brundler MA, Blouin JL, **Foulkes WD**, Hutter P. Double frameshift mutations in APC and MSH2 in the same individual. *Int J Colorectal Dis*, 21:79-83, 2006

--Barker KT, **Foulkes WD**, Schwartz CE, Labadie C, Monsell F, Houlston RS, Harper J. Is the E133K allele of VG5Q associated with Klippel-Trenaunay and other overgrowth syndromes? *J Med Genet*, 2006 Jan 27; [Epub ahead of print]

--Nkondjock A, Ghadirian P, Kotsopoulos J, Lubinski J, Lynch H, Kim-Sing C, Horsman D, Rosen B, Isaacs C, Weber B, **Foulkes WD**, Ainsworth P, Tung N, Eisen A, Friedman E, Eng C, Sun P, Narod SA. Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. *Int J Cancer*, 118:103-7, 2006

--McVety S, Li L, Gordon PH, Chong G, **Foulkes WD**. Disruption of an exon splicing enhancer in exon 3 of MLH1 is the cause of HNPCC in a Quebec family. *J Med Genet*, 43:153-6, 2006

--Mino P, Baker K, Goswami R, Chong G, **Foulkes WD**, Ruszkiewicz A, Barker M, Buchanan D, Young J, Jass JR. Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. *Gut*. 2006 Feb 9; [Epub ahead of print]

--Rudkin TM, Hamel N, Galvez M, Hogervorst F, Gille JJ, Moller P, Apold J, **Foulkes WD**. The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations. *BMC Med Genet*. 2006 Mar 1; 7:15 [Epub ahead of print]

--McVety S, Li L, Thiffault I, Gordon P.H, MacNamara E, Wong N, Australie K, Kasprzak L, Chong G, **Foulkes WD**. The value of multi-modal gene screening in HNPCC in Quebec: three mutations in mismatch repair genes that would have not been correctly identified by genomic DNA sequencing alone. *Familial Cancer*, 5:21-8, 2006

--Oros KK, Leblanc G, Arcand SL, Shen Z, Perret C, Mes-Masson A-M, **Foulkes WD**, Ghadirian P, Provencher D, Tonin PN. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families. *BMC Medical Genetics*, 7:23, 2006

--Li L, McVety S, Younan R, Du Sart D, Gordon PH, Hutter P, Hogervost FBL, Liang P, Chong G, **Foulkes WD**. Distinct patterns of Germ-Line Deletions in MLH1 and MLH2 : the Implication of Alu Repetitive Element in the genetic etiology of Lynch Syndrome (HNPCC). *Hum Mutations*, 27:388, 2006

--Friedman E, Kotsopoulos J, Lubinski J, Lynch HT, Ghadirian P, Neuhausen SL, Isaacs C, Weber B, **Foulkes WD**, Moller P, Rosen B, Kim-Sing C, Gershoni-Baruch R, Ainsworth P, Daly M, Tung N, Eisen A, Olopade OI, Karlan B, Saal HM, Garber JE, Rennert G, Gilchrist D, Eng C, Offit K, Osborne M, Sun P, Narod SA; the Hereditary Breast Cancer Clinical Study Group. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. *Breast Cancer Res*, 2006 Mar 21;8(2):R15 [Epub ahead of print]

--Morel CF, Thomas MA, Cao H, O'Neil CH, Pickering JG, **Foulkes WD**, Hegele RA. A LMNA splicing mutation in two sisters with severe Dunnigan-type familial partial lipodystrophy (FPLD2). *J.Clin.Endocrinol.Metab.* 2006 April 24 [Epub ahead of print]

--Gronwald J, Tung N, **Foulkes WD**, Offit K, Gershoni R, Daly M, Kim-Sing C, Olsson H, Ainsworth P, Eisen A, Saal H, Friedman E, Olopade O, Osborne M, Weitzel J, Lynch H, Ghadirian P, Lubinski J, Sun P, Narod SA. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. *Int J Cancer*, 118:2281-4, 2006

--Narod SA, Lubinski J, Ghadirian P, Lynch HT, Moller P, **Foulkes WD**, Rosen B, Kim-Sing C, Isaacs C, Domcheck S, Sun P; for the Hereditary Breast Cancer Clinical Study Group. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case control study. *Lancet Oncol*, 7:402-406, 2006

--Goswami RS, Mino P, Baker K, Chong G, **Foulkes WD**, Jass JR. Hyperplastic polyposis and cancer of the colon with gastrinoma of the duodenum. *Nat Clin Pract Oncol*, 3 (5): 281-4, 2006
Galiatsatos P, Kasprzak L, Chong G, Jass JR, **Foulkes WD**. Multiple primary malignancies in a patient with situs ambiguous. *Clin Genet*, 69:528-531, 2006

--**Foulkes WD**. BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis. *Fam Cancer*, 5:135-142, 2006

--Shinto E, Baker K, Tsuda H, Mochizuki H, Ueno H, Matsubara O, **Foulkes WD**, Jass JR. Tumor Buds Show Reduced Expression of Laminin-5 gamma 2 Chain in DNA Mismatch Repair Deficient Colorectal Cancer. *Dis. Colon and Rectum*. 2006 June 15 [Epub ahead of print]

--Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, **Foulkes WD**, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA, Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube and peritoneal cancers in women with BRCA1 or BRCA2 mutation. *JAMA*, 296:185-192, 2006

--Baker K, Chong G, **Foulkes WD**, Jass JR. Transforming growth factor-pathway disruption and infiltration of colorectal cancers by intraepithelial lymphocytes. *Histopathology*, 49:371-380, 2006

--Oros, KK, Ghadirian P, Maugard CM, Perret C, Paredes Y, Mes-Masson AM, **Foulkes WD**, Provencher D, Tonin P. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent. *Clin Genet*, 70:320-329, 2006

--Schaid DJ, McDonnell SK, Zarfes KE, Cunningham JM, Hebring S, Thibodeau SN, Eeles RA, Easton DF, **Foulkes WD**, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Badzioch M, Bishop DT, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, Guy M, Hsieh C-L, Halpern J, Balise RR, Oakley-Girvan I, Whittemore AS, Xu J, Dimitrov L, Chang B-L, Adams TS, Turner AR, Meyers DA, Friedrichsen DM, Deutsch K, Kolb S, Janer M, Hood L, Ostrander EA, Stanford JL, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Lange EM, Ho LA, Beebe-Dimmer JL, Wood DP, Cooney KA, Seminara D, Ikonen T, Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela T LJ, Bailey-Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson B-A, Grönberg H, Camp NJ, Farnham J, Cannon-Albright LA, Catalona WJ, Suarez BK, Roehl KA. Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. *Human Genetics*. Aug 25 2006 [Epub ahead of print].

Galiatsatos, Polymnia

--**Galiatsatos P**, Kasprzak L, Chong G, Jass JR, Foulkes WD. Multiple primary malignancies in a patient with situs ambiguus. *Clinical Genetics*, 69:528-531, 2006

--**Galiatsatos P**, Foulkes W. Familial adenomatous polyposis: clinical review. *The American Journal of Gastroenterology*, 101:385-398, 2006

Galipeau, Jacques

--Eliopoulos N, Gagnon RF, Francois M, **Galipeau J**. Erythropoietin Delivery by Genetically-Engineered Bone Marrow Stromal Cells for Correction of Anemia in Mice with Chronic Renal Failure. *Journal of the American Society of Nephrology*, 17:1576-1584, 2006

--Jaalouk D, Crosato M, Brodt P, **Galipeau J** Inhibition of Histone Deacetylation in Retroviral Packaging Cell Lines Markedly Improves the Production of Self-Inactivating Retroviral Vectors. *Virology Journal*, 3:27, 2006

--Jaalouk DE, Lejeune L, Couture C, **Galipeau J**. A Self-Inactivating Retrovector Incorporating the IL-2 Promoter for Activation-Induced Transgene Expression in Genetically Engineered T-Cells. *Virol J*, 21:3:97, 2006 [Epub ahead of print]

--Jimenez T, Fox W, Naus C, **Galipeau J**, Belliveau D. Connexin Over-Expression Differentially Suppresses Glioma Growth and Contributes to the Bystander Effect Following HSV-Thymidine Kinase Gene Therapy. *Cell Communication and Adhesion*, 13:79-92, 2006

--Meriane M, Duhamel S, Lejeune L, **Galipeau J**, Annabi B. Cooperation of matrix metalloproteinases with the RhoA/ROCK and MEK1/ERK signalling pathways is required for the sphingosine-1-phosphate-induced mobilization of marrow-derived stromal cells. *Stem Cells*, 24:2557-2565, 2006

--Pomme S, **Galipeau J**. The use of Mesenchymal Stromal Cells in oncology and cell therapy. *Bulletin du Cancer*, 93:901-7, 2006

--Rafei M, Wu JH, Lejeune L, François M, **Galipeau J**. The Generation of a GMCSF-IL15 transgene (GIFT15) with novel immunosuppressive properties. *Blood*, 2006 Nov 2; [Epub ahead of print]

--Stagg J, Pomme S, Eliopoulos N, **Galipeau J**. Interferon-g-Stimulated Marrow Stromal Cells: A New Type of Non-Hematopoietic Antigen Presenting Cell. *Blood*, 107:2570-2577, 2006

Gambacorti-Passerini, Carlo

--Coluccia AML, Benati D, Dekhil H, Lan C, Marchesi E, **Gambacorti-Passerini C**. Inhibition of Src-mediated beta-Catenin tyrosine phosphorylation in Colorectal cancer cells leads to decreased transcriptional activity and induces a proliferation block. *Cancer Res*, 66:2279-86, 2006

--**Gambacorti-Passerini C**. Prognostic variables in patients with chronic myeloid leukemia treated with imatinib. *Haematological*, 91:145, 2006

--Aloisi A, DI Gregorio S, Stagno F, Guglielmo P, Mannino F, Sormani MP, Bruzzi P, **Gambacorti-Passerini C**, Saglio G, Venuta S, Giustolisi R, Messina A, Vigneri PG. BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of Imatinib Mesylate and Leptomycin B. *Blood*, 107:1591-98, 2006

--Assouline S, Laneuville P, **Gambacorti-Passerini C**. Panniculitis during Dasatinib Therapy for Imatinib-Resistant Chronic Myelogenous Leukemia. *New Engl J of Med*, 354:2623-2625, 2006

--Piazza R, Magistroni V, Franceschino A, Andreoni F, Tornaghi L, Corneo GM, Pogliani E, & **Gambacorti-Passerini C**. The achievement of durable Complete Cytogenetic Remission in late chronic/accelerated phase CML predicts for prolonged response at 6 years. *Blood Cells Molecules and Diseases*, 37:111-115, 2006

--Mologni L, Cazzaniga S, Sala E, Ristagno R, Kuoni T, Puttini M, Bain J, Redaelli S, Riva B, Cohen P, Scapozza L & **Gambacorti-Passerini C**. Inhibition of RET kinase by SU5416. *J. Mol. Endocrinology*, 37:199-212, 2006

--Gunby RH, Amid S, Sottocornola R, Gasser R, Redaelli S, Mologni L, Tartari C, Scapozza L & **Gambacorti-Passerini C**. Structural insights into the ATP binding pocket of the Anaplastic Lymphoma Kinase by site directed mutagenesis, inhibitor binding analysis and homology modeling. *J Med Chem*, 49:5758-68, 2006

--Puttini M, Coluccia AML, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza R, Magistroni V, Andreoni A, Scapozza F, Formelli F, **Gambacorti-Passerini C**. In vitro and in vivo activity of SKI-606, a novel Abl/Src inhibitor against imatinib resistant BCR/ABL+ neoplastic cells. *Cancer Res*, 66:11314-22, 2006

Gatignol Anne

--Levesque K, Halvorsen M, Abrahamyan L, Chatel-Chaix L, Poupon V, Gordon H, DesGroseillers L, **Gatignol A** and Mouland AJ. Trafficking of HIV-1 RNA is mediated by Heterogeneous nuclear ribonucleoprotein A2 expression and impacts on viral assembly *Traffic*, 7:1177-1193, 2006

--Bannwarth S, Laine S, Daher A, Grandvaux N, Clerzius G, LeBlanc AC, Hiscott J, **Gatignol A**. Cell-specific regulation of TRBP1 promoter by NF-Y transcription factor in lymphocytes and astrocytes. *J Mol Biol* 355:898-910, 2006

Greenaway, Christina

--Farhat M, **Greenaway C**, Pai M, Menzies D. "False positive tuberculin skin tests- What is the absolute effect of BCG and non-tuberculous mycobacteria?". *The International J of Tuberculosis and Lung Disease*, 10:1192-1204, 2006

Gyger, Martin

--Al-Shughair N, Al-Dawsari G, **Gyger M**, Mohamed G, Roberts G. Clinical significance of plasmacytosis in the Day +14 bone marrow of acute myeloid leukemia patients undergoing induction chemotherapy. *J Clin Pathol*, 10:1136, 2006

Hilzenrat, Nir

--Lee S, Bain VG, Peltekian K, Krajden M, Yoshida EM, Deschenes M, Heathcote J, Bailey RJ, Simonyi S, Sherman M, and the Canadian Pegasys Study Group: Anderson F, Feinman V, Greenbloom S, **Hilzenrat N**, Kaita K, Marotta P, Scully L, Willems B, Witt-Sullivan H, Worobetz L. Treating chronic hepatitis C with peginterferon alfa-2a (40KD) and ribavirin in clinical practice. *Aliment Pharmacol Ther*, 23:397-408, 2006

--**Hilzenrat N**, Lamoureux E, Cohen A, Baron M. Improved hepatic overlap syndrome with infliximab. *Gastroenterology and Hepatology*, 2:88-89, 2006

--**Hilzenrat N**, Yesovitch R, Shrier I, Stavrakis M, Deschenes M. The effect of information level and coping style on pain and anxiety in needle liver biopsy. *Canadian Journal of Gastroenterology*, 20:597-600, 2006

--Nudo C, Wong P, **Hilzenrat N**, Deschenes M. Elderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C. *Canadian Journal of Gastroenterology*, 20:589-592, 2006

Hirsch, Andrew

--**Hirsch AM**, Kahn SR, et al. PEDS (Pulmonary Embolism Diagnosis Study): A Randomized Controlled Trial of CT Pulmonary Angiography and V/Q Scanning in Patients with Suspected Pulmonary Embolism. *American Journal of Respiratory and Critical Care Medicine*, 3:783, 2006

Hiscott John

--Arguello M, Paz S, Hernandez E, Corriveau-Bourque C, Fawaz L, **Hiscott J**, Lin R. LTA4H expression PEL cells is regulated at the transcriptional level and leads to increased LTB4 production. *J. Immunol.* 176:7051-7061, 2006

--Bannwarth S., Daher A., Grandvaux N., **Hiscott J.**, Gatignol A. Cell specific regulation of TRBP1 by NF-Y transcription factor in lymphocytes and astrocytes *J. Mol. Biol.* 355:898-910, 2006

--Berro R, Kehn K, de la Fuente C, Pumfrey A, Adair R, Wade J, Colberg-Poley AM, **Hiscott J**, Kashanchi F. Acetylated Tat regulates human immunodeficiency virus type 1 splicing through its interaction with the splicing regulator p32. *J. Virol.* 80 :3189-3204, 2006

--Bibeau-Poirier A, Gravel S, Clement J, Meloche S, Grandvaux N, **Hiscott J**, Servant M. Involvement of the IKK-related kinases TBK-1/IKKi and Cullin-based Ubiquitin ligases in IRF-3 degradation. *J. Immunol.* 177:5059-5067, 2006

--Cesaire R, Oliere S, Sharif-Askari E, Loignon M, Lezin A, Olindo S, Panelatti G, Kazanji M, Panasci L, **Hiscott J**. Oncolytic activity of VSV in primary adult T cell leukemia. *Oncogene* 25:349-358, 2006

--Genin P, **Hiscott J**. Chapter 31:Antiviral Actions of the Interferons. in Fundamentals of Molecular Virology, ed. N. Acheson, John Wiley and Son, publishers NY, 333-345, 2006

--**Hiscott J**, Lin R. Inhibition of the interferon antiviral response by hepatitis C virus. *Expert Rev. in Clin. Immunol.* 2:49-58, 2006

--**Hiscott J**, Lin R, Nakhaei P, Paz S. MasterCARD:a priceless link to innate immunity. *Trends in Mol. Medicine* 12:53-56, 2006

--**Hiscott J**, Lacoste J, Lin R. Recruitment of an interferon molecular signaling complex to the mitochondrial membrane: disruption by hepatitis C virus NS3-4A proteolytic cleavage. *Biochem. Pharm.* 72:1477-1484, 2006

--**Hiscott J**, Nguyen N, Arguello M, Nakhaei P, Paz S. Manipulation of the NF- κ B pathway and the innate immune response by viruses. *Oncogene Reviews* 66:6844-6867, 2006

--Pietila TE, Veckman V, Lehtonen A, Lin R, **Hiscott J**, Julkunen I. Multiple NF- κ B and interferon regulatory factors regulate CCL19 gene expression in human monocyte-derived dendritic cells. *J. Immunol.* 178:253-261, 2006

--Mamane Y, **Hiscott J**. Chapter 27: Human T cell leukemia virus type 1: Molecular Biology and Pathogenesis. in Fundamentals of Molecular Virology, ed. N. Acheson, John Wiley and Son, publishers NY, 294-302, 2006

--Nakhaei P, Paz S, **Hiscott J**. Activation of interferon gene expression through Toll-like receptor dependent and independent pathways. In The Interferons – Characterization and Application. Ed. Anthony Meagher, Wiley Publishing Co., 35-73, 2006

--Solis M, Wilkinson P, Romieu R, Hernandez E, Wainberg MA, **Hiscott J**. Gene expression profiling of the host response to HIV-1 B, C or A/E infection in monocyte-derived dendritic cells. *Virology* 352:86-99, 2006

--Solis M, Goubau D, Romieu-Mourez R, Genin P, Civas A, **Hiscott J**. Distinct roles of IRF-3 and IRF-7 in the interferon alpha gene regulation and anti-tumor properties of primary macrophages. *Biochem. Pharm.* 72:1469-1476, 2006

--Civas A, Genin P, Moran P, **Lin R**, Hiscott J. Promoter organization of the interferon-A genes differentially affects virus-induced expression and responsiveness to TBK1 and IKKepsilon. *J. Biol. Chem.* 281:4856-4866, 2006

--Paz S, Sun Q, Nakhaei P, Romieu-Mourez R, Goubau D, Julkunen I, **Lin R**, Hiscott J. RIG-I mediated induction of IRF -3 and IRF-7 phosphorylation. *Cell Mol. Biol.* 52 :17-28, 2006

--Harris, J, Sharma S, Sun Q, Oliere S, **Lin R**, Hiscott J, Grandvaux N. Nuclear Accumulation of c-Rel following C-terminal phosphorylation by TBK1/IKKepsilon. *J. Immunol.* 177:2527-2535, 2006

--Romieu-Mourez R, Solis M, Nardin A, Goubau D, Baron-Bodo V, **Lin R**, Massie B, Salcedo M, Hiscott J. Distinct roles for IFN regulatory factor (IRF)-3 and IRF-7 in the activation of antitumor properties of human macrophages. *Cancer Res* 66(21):10576-85, 2006

Hoffer, L. John

--**Hoffer LJ**. Metabolic consequences of starvation. IN: Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ, eds, Modern Nutrition in Health and Disease, 10th Edition. Baltimore, MD: Williams & Wilkins, 730-748, 2006

-- **Hoffer LJ**. Optimum protein intake in hypocaloric states. IN: Nutrition Composition of Rations for Short-term, High-intensity Combat. Washington DC, Institute of Medicine, National Academy Press, 235-242, 2006

-- Padayatty SJ, Riordan HD, Hewitt SM, Katz A, **Hoffer LJ**, Levine M. Intravenously administered vitamin C as cancer treatment: three cases. *CMAJ* 174:937-942, 2006

-- **Hoffer LJ**. Testing the homocysteine hypothesis in end-stage renal disease: problems and a possible solution. *Kidney International* 69:1507-1510, 2006

-- **Hoffer LJ**. Nutritional supplements for adults. In: Gray, J., ed. Therapeutic Choices [Internet]. Ottawa (ON): Canadian Pharmacists Association; 2003 [updated 2006; cited 2006 May 12]. Available from: <https://www.e-therapeutics.ca/wps/portal/!ut/p/.scr/Login>

-- **Hoffer LJ**. Tube feeding in advanced dementia: the metabolic perspective. *BMJ* 333:1214-1215, 2006

Honos, George

--Hemmelgam BR, McAssister FA, Grover S, Myers MG, McKay DW, Bolli P, Abbott C, Schiffrin EL, **Honos G**, Burgess E, Mann K, Wilson T, Penner B, Tremblay G, Milot A, Chockalingam A, Touyz RM, Tobe SW for the Canadian Hypertension Education Program. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - Blood pressure measurement, diagnosis, and assessment of risk. *Can J Cardiol*, 22:573-581, 2006

--Khan NA, McAllister FA, Rabkin SW et al. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. *Can J Cardiol*, 22: 583-593, 2006

--Drouin D, Campbell NR, Kaczorowski J. for the Canadian Hypertension Education Program and the Implementation Task Force. The implementation of recommendations on hypertension: the Canadian Hypertension Program. *Can J Cardiology*, 22:595-598, 2006

--The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. *Lancet*, 367:1903-1912, 2006

Hudson, Marie

--Suisa S, Bernatsky S, **Hudson M**. Anti-rheumatic Drug Use and the Risk of Acute Myocardial Infarction. *Arthritis and Rheumatism*, 55:531-536, 2006

--Suisa S, **Hudson M**, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. *Arthritis and Rheumatism*, 54:1435-9, 2006

Kahn, Susan R.

--Kramer, MS, Chen, MF, Roy, I, Dassa, C, Lamoureux, J, **Kahn, SR**, McNamara, H and Platt, R for the Montreal Prematurity Study Group. Intra- and inter-observer agreement and statistical clustering of placental histopathologic features relevant to preterm birth. *Am J Obs Gyn*, 195:1674-9, 2006

--Hull RD, Pineo GF, Brant RFM, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon M-C and LITE Investigators (includes **Kahn SR**). Long-term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with Cancer. *The American Journal of Medicine*, 119:1062-1072, 2006

--*Opatrny L, David M, **Kahn SR**, Shrier I, Rey E. The association between traditional and newer antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: A meta-analysis. *J Rheumatol*, 33:2214-21, 2006

--**Kahn SR**, Ducruet T, Lamping DL, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassir J, Solymoss S, Desjardins L. The VEINES-QOL/Sym questionnaire is a valid and reliable measure of quality of life and symptoms in patients with deep venous thrombosis. *J Clin Epidemiol*, 59:1049-56, 2006

--**Kahn SR**. The post-thrombotic syndrome: progress and pitfalls. *Br J Haematol*, 134:357-65, 2006

--**Kahn SR**. Frequency and determinants of the post-thrombotic syndrome after venous thromboembolism. *Curr Opin Pulm Med*, 12:299-303, 2006

--**Kahn SR**. Review: Horse chestnut seed extract for chronic venous insufficiency. *ACP Journal Club*, 145:20, 2006

--**Kahn SR**, Desmarais S, Ducruet T, Arsenault L, Ginsberg JS. Comparison of the Villalta and Ginsberg clinical scales to diagnose the post-thrombotic syndrome: correlation with patient-reported disease burden and venous valvular reflux. *J Thromb Haemost*, 4:907-908, 2006

--*Elman ER, **Kahn SR**. The post-thrombotic syndrome after upper extremity deep venous thrombosis: A systematic review. *Thrombosis Research*, 117:609-614, 2006

--**Kahn SR**. The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis. *J Thrombosis Thrombolysis*, 21:41-48, 2006

Karaplis, Andrew

--Hendy GN, Li T, Girard M, Feldstein RC, Mulay S, Desjardins R, Day R, **Karaplis AC**, Tremblay ML, Canaff L. Targeted ablation of the chromogranin A (Chga) gene: normal neuroendocrine dense core secretory granules and increased expression of other granins. *Mol Endocrinol* 2006

Kleiman, Lawrence

--Roy B, Hu J, Guo X, Russell RS, Guo F, **Kleiman L**, Liang C. Association of RNA helicase A with human immunodeficiency virus type 1 particles. *J Biol Chem*. 281:12625-12635, 2006

--Kovaleski BJ, Kennedy R, Hong MK, Datta SA, **Kleiman L**, Rein, A., and Musier-Forsyth, K. In vitro characterization of the interaction between HIV-1 Gag and human lysyl-tRNA synthetase. *J Biol Chem*, 281:19449-19456, 2006

--Guo F, Cen S, Niu M, Saadatmand J, and **Kleiman, L**. The inhibition of tRNA^{Lys}-primed reverse transcription by human APOBEC3G during HIV-1 replication. *J Virol*, 80: 11710-11722, 2006

Langleben, David

--**Langleben D**, Dupuis J, Langleben I, Hirsch AM, Baron M, Senecal JL, Giovinazzo M. Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertension. *Chest*, 129:689-95, 2006

--Barst RJ, **Langleben D**, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galie N. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. *J Am Coll Cardiol*, 47:2049-2056, 2006

--Walker AM, **Langleben D**, Korelitz JJ, Rich S, Rubin LJ, Strom BL, Gonin R, Keast S, Badesch D, Barst R, Bourge R, Channick R, Frost A, Gaine S, McGoon M, McLaughlin V, Murali S, Oudiz R, Robbins I, Tapson V, Constantine G. Temporal trends and drug exposures in pulmonary hypertension: An American experience. *Am Heart J*, 152:521-526, 2006

LeBlanc, Andrea

--Bounhar, Y., Roucou, X., **LeBlanc, A.C**. Prion protein prevents Bax-mediated cell death in absence of other Bcl-2 family members in *Saccharomyces Cerevisiae*. *FEMS Yeast Research*, 6:1204-12, 2006

--Gains, M.J., Roth, K.A., **LeBlanc, A.C**. Prion protein protects neurons from ethanol-induced Bax-mediated cell death in vivo. *Neuroreport*, 17:903-6, 2006

--Guo H, Petrin D, Zhang Y, Bergeron C, Goodyer CG, and **LeBlanc AC**. Caspase-1 activation of Caspase-6 in human apoptotic neurons. *Cell Death and Differentiation*. 13:285-92, 2006

Liang, Chen

--Roy BB, Russell RS, Turner D, and **Liang C**. The T12I mutation within the SP1 region of Gag restricts packaging of spliced viral RNA into human immunodeficiency virus type 1 with mutated RNA packaging signals and mutated nucleocapsid sequence. *Virology* 344:304-14, 2006

Lipman, Mark

--Shen Y, Young B, Lipman ML. Suppression of cell-mediated immune responses by a Fas-immunoglobulin fusion protein. *Transplantation*, 81:1041-1048, 2006

Lin, Rongtuan

--Siren J, T Imaizumi, D Sarkar, T Pietila, D Noah, **R Lin**, J Hiscott, R Krug, P Fisher, I Julkunen, S Matikainen, Retinoic acid inducible gene-I and mda-5 are involved in influenza A virus-induced expression of antiviral cytokines. *Microbes Infect*, 8:2013-20, 2006

--Kaukinen P, Sillianpaa M, Kotenko S, **Lin R**, Hiscott J, Melen K, Julkunen I. Hepatitis C virus NS2 and NS3/4A proteins are potent inhibitors of host cell cytokine/chemokine gene expression. *Virol. J.* 3:66-73, 2006

--**Lin R**, Lacoste J, Nakhaei P, Sun Q, Paz S, Yang L, Julkunen I, Meurs E, Hiscott J. Dissociation of a MAVS/IPS/VISA/Cardif and IKKepsilon complex from the mitochondrial outer membrane by NS3/4A proteolytic cleavage. *J. Virol.* 80:6072-6083, 2006

--**Lin R**, Nakhaei P, Yang L, Sharif-Askari E, Julkunen I, Hiscott J. Negative regulation of the RIG-I induced antiviral state by the ubiquitin editing protein A20. *J. Biol. Chem.* 281:2095-2103, 2006

--Matikainen S, J Sirén, J Tissari, V Veckman, J Pirhonen, M Severa, Q Sun, **R Lin**, S Meri, G Uzé, J Hiscott, and I Julkunen. TNF upregulates the expression of IKK epsilon and RIG-I and enhances the expression of antiviral cytokines during influenza A virus infection. *J Virol*, 80:3515-22, 2006

--Goriely, S, C Molle, M Nguyen, V Albarani, N Haddou, **R Lin**, D De Wit, V Flamand, F Willems and M Goldman. Interferon regulatory factor 3 is involved in Toll like receptor (TLR)4- and TLR3-induced IL-12p35 gene activation. *Blood*, 107:1078-84, 2006

MacNamara, Elizabeth

--McVety S, Li L, Thiffault I, Gordon PH, **MacNamara E**, Wong N, Australie K, Kasprzak L, Chong G, Foulkes WD, The value of Multi-Modal Gene Screening in HNPCC in Quebec: three

mutations in mismatch repair genes that would have not been correctly identified by genomic DNA sequencing alone. *Familial Cancer*, 51: 21-28, 2006

Miller, Mark

--Boyd DA, **Miller MA** and Mulvey MR. *E.gallinarum* N04-0414 harbors a VanD-type Vancomycin resistance operon and does not contain a D-alanine: D-alanine 2 (ddl2) gene. *Antimicrobial Agents & Chemotherapy*, 50:1067-70, 2006.

--D Beer G, **Miller MA**, Tremblay L, Monette J. An outbreak of scabies in a long-term care facility: The role of misdiagnosis and the costs associated with control. *Infection Control and Hospital Epidemiology*, 27:517-18, 2006

Miller, Wilson H. Jr.

--Colombo M, Colosimo A, Davison K, Diaz Z, Gao W, Guo Qi, Mader S, Mann KK, **Miller WH Jr.**, Padovani AMS, Scrivens PJ, Antimony trioxide-induced apoptosis is dependent on JNK signaling. *Toxicology Letters*, 160:158-170, 2006

--Bhaumik M, Cai LF, Kakizuka A, Majid SM, Matsushita H, **Miller WH Jr.**, Miyachi H, Pandolfi PP, Rego EM, Scaglioni PP, In vivo analysis of the role of aberrant HDAC recruitment and RARa blockade in the pathogenesis of APL. *J Exp Med* 203:821-828, 2006

--Bellincampi L, Bernardini S, Bonati A, Federici G, Lo Coco F, Lunghi P, Mann, KK, **Miller WH Jr**, Mucetelli M, Noguera NI. Role of GSTP1-1 in mediating the effect of As₂O₃ in the acute promyelocytic leukemia cell line NB4. *Ann Hematol* 85:681-687, 2006

--Assouline S and Miller WH Jr. High Dose Vitamin C: New Hope or False Promise? *Can Med Assoc J*, 174: 956-957, 2006

Monette, Johanne

--De Beer G, **Monette J**, Miller M, Tremblay L. An outbreak of scabies in a long term care facility: the role of mis-diagnossis and cost associated with control. *Infect Control Hosp Epidemiol.* 5:517-8, 2006

--Landreville P, Bédard A, Verrault R, Desrosiers J, Champoux N, **Monette J**, Voyer P. Non pharmacological treatment of aggressive behaviors related to dementia. *Int Psychogeriatr.* 18 (1) 47-73, 2006

--Payot I, **Monette J**, Béland F, Laurier C, Bergman H, Mallet L, Le Cruguel JP. Problèmes reliés à la pharmacothérapie comme cause d'hospitalisation chez la personne âgée fragile. *Revue de Gériatrie.* 31:785-794, 2006

Palayew, Mark

--Baltzan M, Kassissia I, Elkholi O, **Palayew M**, et al. Prevalence of Persistent Sleep Apnea in Patients Treated with Continuous Positive Airway Pressure. *Sleep*, 29:557-563, 2006

--Ellen R, Marshall S, **Palayew M**, et al. Systemic Review of Motor Vehicle Crash Risk in Persons with Sleep Apnea. *Journal of Clinical Sleep Medicine*, 2:193-200, 2006

Panasci, Lawrence

--Cesaire R, Oliere S, Sharif-Askari E, Loignon M, Lezin A, Olindo S, Panelatti G, Kazanji M, Aloyz R, **Panasci LC**, Bell JC, Hiscott J. Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia. *Oncogene* 25:349-358, 2006

--**Panasci LC**. Effect of tamoxifen after chemotherapy in hormone receptor-positive, node-negative breast cancer. *J Clin Oncol*, 24:2392, 2006

--Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR and **Panasci LC**. Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multi-Centre Phase II Trial. *J Clin Oncol* 24(18):2773-8, 2006.

--Huynh H, Soo KC, Chow PK, **Panasci LC** and Tran E. Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. *Clin Cancer Res* 12(14 Pt 1):14306-14, 2006

Pantopoulos, Kostas

--Nie G, Chen G, Sheftel A, Mikhael M, **Pantopoulos K**, Ponka P. Mitochondrial ferritin expression inhibits implanted tumor growth via an iron-dependent mechanism, *Blood*, 108:2428-2434, 2006

--Wang J, Fillebeen C, Chen G, Andriopoulos B, **Pantopoulos K**. Sodium nitroprusside promotes IRP2 degradation via an increase in intracellular iron and in the absence of S-nitrosylation at C178, *Mol. Cell. Biol.*, 26:1948-1954, 2006

--Andriopoulos B, **Pantopoulos K**. Heparin generated by hepatoma cells inhibits iron export from co-cultured THP-1 monocytes, *J. Hepatol.*, 44:1125-1131, 2006

--Harrison-Findik DD, Schafer D, Klein E, Timchenko N, Kulaksiz H, Clemens D, Fein E, Andriopoulos B, **Pantopoulos K**, Gollan J. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression, *J. Biol. Chem.*, 281:22974-22982, 2006

Pepe, Carmela

--**C Pepe**, F Shepherd. EGFR Inhibitors in Treatment of Non-Small Cell Lung Cancer. *Oncology Exchange*, 5:23-26, 2006

Pollak, Michael

--Ahn J, Weinstein SJ, Snyder K, **Pollak MN**, Virtamo J, Albanes D. No association between serum insulin-like growth factor (IGF)-I, IGF-binding protein-3, and lung cancer risk. *Cancer Epidemiol Biomarkers Prev.* 15 :2010-2, 2006.

--Diorio C, Berube S, Byrne C, Masse B, Hebert-Croteau N, Yaffe M, Cote G, **Pollak M**, Brisson J. Influence of Insulin-like Growth Factors on the Strength of the Relation of Vitamin D and Calcium Intakes to Mammographic Breast Density. *Cancer Res.* 14: 588-597, 2006.

--Gong, Z., Neuhouser, M.L., Goodman, P.J., Albanes, D., Chi, C., Hsing, A.W., Lippman, S.M., Platz, E.A., **Pollak, M.N.**, Thompson, I.M., Kristal, A.R. Obesity, Diabetes, and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial. *Epidemiol Biomarkers Prev.* 15:1977-83, 2006.

--Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, Blouin MJ, Zhao Y, **Pollak MN**. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. *Gynecol Oncol.* 100: 389-96, 2006.

--Harris TG, Strickler HD, Yu H, **Pollak MN**, Monrad ES, Travin MI, Xue X, Rohan TE, Kaplan RC. Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3). *Growth Horm IGF Res.* 16:86-92, 2006

--Liu, B., Lee, KW., Anzo, M., Zhang, B., Zi, X., Tao, Y., Shiry, L., **Pollak, M.**, Lin, S., Cohen, P. Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. *Oncogene.* 2006 Sep 18; [Epub ahead of print]

--Rollison DE, Newschaffer CJ, Tao Y, **Pollak M**, Helzlsouer KJ. Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer. *Int J Cancer.* 118: 1279-84, 2006.

--Rousseau MC, Parent ME, **Pollak MN**, Siemiatycki J. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. *Int J Cancer.* 118: 2105-2109, 2006.

--Schernhammer ES, Holly JM, Hunter DJ, **Pollak MN**, Hankinson SE. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. *Endocr Relat Cancer.* 13:583-592, 2006

--So, Alan., Levitt, R.J., Eigl, B., Fazil, L., Muramaki, M., Nielsen, T., Gleave, M., **Pollak, M.** Insulin-like growth factor binding protein-2 expression in breast cancer is associated with aggressive behavior and represents a novel molecular target for therapy. (Submitted)

--Tran CD, Diorio C, Berube S, **Pollak M**, Brisson J. Relation of insulin-like growth factor (IGF) I and IGF-binding protein 3 concentrations with intakes of fruit, vegetables, and antioxidants. *Am J Clin Nutr.* 84(6):1518-26, 2006.

--Tseng PH, Weng SC, Wang YC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, **Pollak M**, Chen CS. Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived PDK-1 Inhibitor. *Mol Pharmacol.* 70:1534-41, 2006

--Wei EK, Ma J, **Pollak MN**, Rifai N, Fuchs CS, Hankinson SE, Giovannucci E. C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. *Cancer Epidemiol Biomarkers Prev.* 15:750-5, 2006

--Zakikhani, M., Dowling, R., Fantus, G.I., Sonenberg, N., **Pollak, M.** Metformin is an AMP-kinase dependent growth inhibitor for breast cancer cells. *Cancer Research*, 66: 10269-73, 2006

--Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, **Pollak MN**, Hankinson SE. Reproducibility of Plasma Steroid Hormones, Prolactin, and Insulin-like Growth Factor Levels among Premenopausal Women over a 2- to 3-Year Period. *Cancer Epidemiol Biomarkers Prev.* 15:972-8, 2006

Ponka, Prem

--Kovarikova P, Klimes J, Sterba M, Popelova O, Gersl V, **Ponka P.** HPLC determination of a novel aroylhydrazone iron chelator (o-108) in rabbit plasma and its application to a pilot pharmacokinetic study. *J Chromatogr B Analyt Technol Biomed Life Sci*, 838, 107-112, 2006

--Mikhael M, Kim SF, Schranzhofer M, Soe-Lin S, Sheftel AD, Mullner E, **Ponka P.** Iron regulatory protein-independent regulation of ferritin synthesis by nitrogen monoxide. *FEBS J* 273:3828-3836, 2006

--**Ponka P.** Genetically-based iron deficient erythropoiesis. *HEMATOLOGY eDIGEST Newsletter (The Johns Hopkins University School of Medicine)*, 1:8, 2006)

--**Ponka P**, Sheftel AD. It's hepcidin again, but is it the only master? *Blood* 108, 3631-3632, 2006

--**Ponka P**, Tenenbein M, Eaton J. Iron. In: Handbook on Toxicology of Metals, Third Ed. (G Nordberg, BA Fowler, M Nordberg, L Fridberg, eds.) Elsevier, 2006

--Sterba M, Popelova O, Simunek T, Marzurova Y, Potacova A, Adamcova M, Kaiserova H, **Ponka P**, Gersl V. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorbenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity. *J Pharm and Exp Therap*, 319:1336-1347, 2006

--Watts RN, Hawkins C, **Ponka P***, Richardson DR. Nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-induced glutathione efflux via multidrug resistance-associated protein 1. *Proc Natl Acad Sci USA*, 103:7670-7675, 2006 *Corresponding author

--Whitnall M, Howard J, **Ponka P***, Richardson DR. A novel class of iron chelators with a wide spectrum of potent anti-tumor activity that overcomes resistance to chemotherapeutics. *Proc Natl Acad Sci USA*, 103:14901-14906, 2006. *Corresponding author

--Yoon D, Pastore YD, Divoky V, Liu E, Mlodnicka AE, Rainey K, **Ponka P**, Semenza GL, Schumacher A, Prchal JT, Schumacher A, Prchal JT. HIF-1 alpha-deficiency result in dysregulated EPO signaling and iron homeostasis in mouse development. *J Biol Chem*, 281:25703-25711, 2006

--Zhang AS, Sheftel AD, **Ponka P**. The anemia of "hemoglobin deficit" (hbd/hbd) mice is caused by a defect in transferrin cycling. *Exp Hematol*, 34:593-598, 2006

Rosenblatt, David

--Worgan LC, Niles K, Tirone JC, Hofmann A, Verner A, Sammak A, Kucic T, Lepage P, and Rosenblatt DS: The spectrum of mutations in mut methylmalonic academia and identification of a common Hispanic mutation and haplotype. *Hum Mutat*. 27:31-43, 2006

--Moras E, Hosack A, Watkins D, Rosenblatt DS: Mitochondrial vitamin B12-binding proteins in patients with inborn errors of cobalamin metabolism. *Mol Gen Metab*, 90:140-147, 2006

--Lerner-Ellis JP, Tirone JC, Pawelek PD, Dore C, Atkinson JL, Watkins D, Morel CF, Fujiwara TM, Moras E, Hossack AR, Dunbar GV, Antonicka H, Forgetta V, Fobson CM, Leclerc D, Gravel RA, Shoubridge EA, Coulton JW, Lepage P, Rommens JM, Morgan K, **Rosenblatt DS**: Identification of the gene responsible for methylmalonic aciduria and homocystinuria, cblC type. *Nat Genet* 38:93-100, 2006

--Zhang J, Dobson CM, Wu X, Lerner-Ellis JP, **Rosenblatt DS**, Gravel RA: Impact of cblB mutations on the function of ATP:COB(I)ALAMIN adenosyltransferase in disorders of vitamin B12 metabolism. *Mol Genet Metab* (87):315-322, 2006

--Lerner-Ellis JP, Gradinger AB, Watkins D, Tirone JC, Villeneuve A, Lepage P, Dobson CM, Gravel RA, **Rosenblatt DS**: Mutation and biochemical analysis of patients belonging to the cblB complementation class of vitamin B-12 dependent methylmalonic aciduria. *Mol Genet Metab* (87):219-225, 2006

--Dobson CM, Gradinger AB, Longo N, Wu X, Leclerc D, Lerner-Ellis JP, Lemieux M, Belair C, Watkins D, **Rosenblatt DS**, Gravel RA: Homozygous nonsense mutation in the MCEE gene and siRNA suppression of methylmalonyl-CoA epimerase expression: A novel cause of mild methylmalonic aciduria. *Mol Genet Metab* (88):327-333, 2006

--Morel CF, Lerner-Ellis JP, **Rosenblatt DS**: Combined methylmalonic aciduria and homocystinuria (cblC): Phenotype-genotype correlations and ethnic-specific observations. *Mol Genet Metab* (88):315-321, 2006

--Bikker H, Bakker HD, Abeling NGGM, Poll-The BT, Kleijer WJ, **Rosenblatt DS**, Waterham HR, Wanders RJA Duran M: A homozygous nonsense mutation in the methylmalonyl-CoA epimerase gene results in mild methylmalonic aciduria. *Human Mutation* 27:640-643, 2006

--Ernest S, Carter M, Shao H, Hosack A, Lerner N, Colmenares C, **Rosenblatt DS**, Yoh-Han Pao, Ross ME, Nadeau J: Parallel changes in metabolite and expression profiles in Crooked-tail mutant and folate-reduced wild-type mice. *Human Mol Genet* 15(23):3387-93, 2006

-- **Rosenblatt DS**, and Fowler B: Disorders of cobalamin and folate transport and metabolism, in *Inborn Metabolic Diseases* (4th ed), J. Fernandes, J.M. Saudubray, G. van den Berghe, J.H. Walter, (eds) Springer-Verlag Berlin Heidelberg, 341-356, 2006

Rudski, Lawrence

--Wong, GC, Marcotte F, **Rudski LG**. Impact of chronic Lisinopril therapy on left atrial volume versus dimension in chronic organic mitral regurgitation. *Canadian Journal of Cardiology*, 22:125-129, 2006

Schiffrin, Ernesto L.

--Benkirane K, Amiri F, Diep QN, El Mabrouk M, **Schiffrin EL**. PPAR- γ : inhibits angiotensin II-induced cell growth via SHIP2 and 4E-BP1. *Am J Physiol (Heart Circul Physiol)*, 290:H390-H397, 2006

--Brassard P, Amiri F, Thibault G, **Schiffrin EL**. Role of Angiotensin Type-1 and Angiotensin Type-2 Receptors in the Expression of Vascular Integrins in Angiotensin II-Infused Rats. *Hypertension*, 47:122-127, 2006

--Benkirane K, Viel EC, Amiri F, **Schiffrin EL**. Peroxisome Proliferator-Activated Receptor γ : Regulates Angiotensin II-Stimulated Phosphatidylinositol 3-Kinase and Mitogen-Activated Protein Kinase in Blood Vessels in Vivo. *Hypertension*, 47:102-108, 2006

--Savoia C, **Schiffrin EL**. Inflammation in hypertension. *Curr Opin Nephrol Hypertens*, 15:152-158, 2006

--**Schiffrin EL**. Effects of aldosterone on the vasculature. *Hypertension Highlights*. *Hypertension* 47:312-318, 2006

--Savoia C, Touyz RM, He Y, Endermann D, Pu Q, Ko EA, De Ciuceis C, **Schiffrin EL**. Angiotensin Receptor Blocker Added to Previous Antihypertensive Agents on Arteries of Diabetic Hypertensive Patients. *Hypertension*, 48:271-277, 2006

--White M, Ducharme A, Ibrahim R, Whittom L, Lavoie J, Guertin M-C, Racine N, He Y, Yao G, Rouleau JL, **Schiffrin EL**, Touyz RM. Systemic inflammation and oxidative stress are increased in patients with worsening congestive heart failure: Improvement after short-term inotropic support. *Clin Sci*, 110:384-389, 2006

--Touyz RM, **Schiffrin EL**. Peroxisome Proliferator Activated Receptors in Vascular Biology – Molecular Mechanisms and Clinical Implications. *Vascular Pharmacology*, 45:19-28, 2006

--Savoia C, **Schiffrin EL**. Inhibition of the Renin Angiotensin System: Implications for the Endothelium. *Current Diabetes Reports*, 6:274-278, 2006

--Javeshghani D, Sairam MR, Fritsch Neves M, **Schiffrin EL**, Touyz RM. Angiotensin II Induces Vascular Dysfunction without Exacerbating Blood Pressure Elevation in a Mouse Model of Menopause-associated Hypertension. *J Hypertens*, 24:1365-1373, 2006

--Savoia C, Ebrahimian T, He Y, Gratton J-P, **Schiffrin EL**, Touyz RM. Angiotensin II/AT2 Receptor-Induced Vasodilation in SHRSP Involves Nitric Oxide and cGMP-Dependent Protein Kinase. *J Hypertens*, 24:2417-2422, 2006

--**Schiffrin EL**. Role of vascular endothelin in hypertension. Chapter 17 In: Molecular Mechanisms of Hypertension, 1st Edition, Re RN, DiPette D, **Schiffrin EL** and Sowers JR. Eds., Taylor & Francis, London, UK, Chapter 17, 155-161, 2006

--Molecular Mechanisms in Hypertension, Eds. RN Re, DJ DiPette, **EL Schiffrin**, JR Sowers. Taylor & Francis Medical Books, 2006

Schipper, Hyman

--Song W, Su H, Song S, Paudel HK, **Schipper HM**. Over-expression of heme oxygenase-1 promotes oxidative mitochondrial damage in rat astroglia. *J Cell Physiol* 206: 655-663, 2006

--**Schipper HM**, Bennett DA, Liberman A, Bienias L, Schneider JA, Kelly J, Arvanitakis Z. Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. *Neurobiol Aging*. 27: 252–261, 2006

--Segal LM, Walker A, Marmor E, Stern E, Levental M, Glikstein RS, **Schipper HM**. Altered mental status and a retro-auricular mass. *Can J Neurol Sci*. 33: 317-319, 2006

Sheppard, Richard

-Kahn R and **Sheppard R**. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. *Immunology*, 118: 10-24, 2006

--**Sheppard R** and McNamara D. Pharmacogenetics, in Heart Failure - Pharmacologic Management, Ed. Arthur M Feldman, Williston Blackwell Publishing, 2006

Small, David

--Harold S Nelson and the SMART Study Group including **Small, D.** The Salmeterol Multicenter Asthma Research Trial: A Comparison of Usual Pharmacotherapy for Asthma or Usual Pharmacotherapy Plus Salmeterol, *Chest*, 129, 2006

--Nguyen A, Baltzan M., **Small D**, Wolkove N, Guillon S, Palayew M. Clinical Reproducibility of the Epworth Sleepiness Scale. *Journal of Clinical Sleep Medicine*, 2:170-174, 2006

--G Kasymjanova, **D Small** et al. Does Granulocyte Colony Stimulating Factor (G-CSF) Affect Survival in Patients with Advanced Non Small Cell Lung Cancer? *Journal of Thoracic Oncology*, 1:564, 2006

Small, Peter

-- Leith E, Bowen T, Butchey J, Fischer D, Kim H, Moote B, **Small P**, Stark D, Wasserman S Consensus Guidelines on Practical Issues of Immunotherapy-Canadian Society of Allergy and Clinical Immunology (CSACI). *Allergy, Asthma, and Clinical Immunology*, 2:47-61, 2006

Szilagyi, Andrew

--**Szilagyi A**, Nathwani U, Vinokuroff C, JA Correa JA, Shier I. Evaluation of relationships among national colorectal cancer mortality rates, genetic lactase non persistence status and per capita yearly milk and milk product consumption. *Nutrition and Cancer*, 55:151-156, 2006

--**Szilagyi A**, Nathwani U, Vinokuroff C, Correa JA, Shier I. The effect of lactose maldigestion on the relationship between dairy food intake and colorectal cancer: A systematic review. *Nutrition and Cancer*, 55:141-150, 2006

--Malolepszy P, Shrier I, **Szilagyi A**. Adaptation to lactose intolerance is not achieved by long term ingestion of a multi species containing probiotic. *International Journal of Probiotics and Prebiotics*, 1:113-120, 2006

--Al-Hamoudi WK, Zalpert L, **Szilagyi A**. Acute Symptomatic Gastritis due to *Helicobacter heilmannii*. *Helicobacter*, 11:446-450, 2006

-- **Szilagyi A**, Ghali MP. Pharmacological therapy of gastrointestinal vascular malformations. *Can J Gastroenterol*, 20: 171-178, 2006

Therrien, Judith

--**Therrien J**, Rambilhar S, Newman B, Siminovitch K, Langleben D, Webb G, Granton J. Eisenmenger syndrome and atrial septal defect: Nature of Nature? *Can J Cardiol*, 22:1133-1136, 2006

--**Therrien J**. Chapter 4: LVOT Obstruction. *American College of Cardiology Echo SAP 5*, 2006

Tischkowitz, Marc

--Robin NH, Taylor CJ, McDonald-McGinn DM, Zackai EH, Bingham P, Collins KJ, Earl D, Gill D, Granata T, Guerrini R, Katz N, Kimonis V, Lin JP, Lynch DR, Mohammed SN, Massey RF, McDonald M, Rogers RC, Splitt M, Stevens CA, **Tischkowitz MD**, Stoodley N, Leventer RJ, Pilz DT, Dobyns WB. Polymicrogyria and deletion 22q11.2 syndrome: window to the etiology of a common cortical malformation. *Am J Med Genet A*, 15; 140(22):2416-25, 2006

--Vogt J, Ryan E, **Tischkowitz MD**, Reardon W, Brueton LA. The tale of a nail sign in chromosome 4q34 deletion syndrome. *Clin Dysmorphol.*, 15:127-32, 2006

--**Tischkowitz MD**, Foulkes WD. The basal phenotype of BRCA1-Related Breast Cancer: Past, Present and Future. *Cell Cycle*, 5:963-7, 2006

--**Tischkowitz M**, Gologan A, Srolovitz H, Khanna M, Foulkes WD. Muir Torre syndrome and MSH2 mutations: the importance of dermatological awareness. *Br J Cancer*, 95: 243-244, 2006

Wolfson, Christina

--Auger C, Demers L, Derosiers J, Giroux F, Ska B, **Wolfson C**. Applicability of a toolkit for geriatric rehabilitation outcomes. Preprint in *Disability and Rehabilitation*. Online Date, June 30, 2006.

--Vida S, Galbaud du Fort G, Kakuma R, Arsenault L, Platt R, **Wolfson C**. An 18-month prospective cohort study of functional outcome of delirium in the elderly: *Activities of Daily Living*. *International Psychogeriatrics*, 18:681-700, 2006

7. APPENDIX A. DIVISIONAL REPORTS

(See attached reports)